Lemierre’s syndrome with muscle necrosis and chronic osteomyelitis

Latif, Azka; Ahsan, Muhammad Junaid; Yousaf, Amman; Tameezuddin, Asim; Sood, Akshat; Thirumalareddy, Joseph

doi:10.1080/08998280.2020.1864702

Cited by 1 publication

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This perspective is also reflected in the only retro-perspective study available that studied about 700 cases of LS from 2000 to 2017 and concluded that there are no disease-specific elements of concern regarding the safety of anticoagulation in LS [ 12 ]. From our analysis of 26 LS cases from 2016 to 2021, anticoagulation was used in 76% of cases and the average duration was 9.8 weeks (ranging from 1 week to 16 weeks; Table 2 [ 4 , 17 , 21 – 38 , 41 – 44 ]. In our case, due to the absence of thrombophlebitis/IJV thrombosis, no therapeutic anticoagulation was considered.…”

Section: Discussionmentioning

confidence: 99%

“…Regarding the duration of antibiotics, Riordan, 2007, referenced an estimate of 9 to 84 days with an average of 42 days [2]. We have analyzed 26 cases of LS from 2016 to 2021, and the average antibiotics duration was 5.3 weeks (Table 2) [4,17,[21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][42][43][44]. In clinical practice, due to the lack of an established guideline, the duration and selection of antibiotics highly varied based on clinical responses in patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lemierre Syndrome: A Diagnosis behind the Veil

Nwabara

Gvazava

et al. 2023

Case Reports in Infectious Diseases

View full text Add to dashboard Cite

Lemierre syndrome (LS) is a rare, serious infection that is often misdiagnosed, as it frequently mimics common upper respiratory infections. It is even rarer for LS to be preceded by a viral infection. We share a case of LS in a young man who presented to the Emergency Department with COVID-19 viral infection followed by a subsequent LS diagnosis. The patient’s condition initially worsened despite treatments for COVID-19 and was subsequently started on broad-spectrum antibiotics. He was then diagnosed with LS after blood cultures grew Fusobacterium necrophorum, and antibiotics were adjusted accordingly, resulting in improvement of symptoms. Even though LS is often recognized as a sequela of bacterial pharyngitis, preceding viral infections, including COVID-19, might be a risk factor that contributes to the development of LS.

show abstract